New GLP-1 Complaint Alleges Novo Nordisk Failed to Warn of Ileus Risks
A new complaint in the GLP-1 multidistrict litigation accuses Novo Nordisk of failing to warn patients about the risk of ileus and intestinal obstruction from Ozempic.
A new complaint in the GLP-1 multidistrict litigation accuses Novo Nordisk of failing to warn patients about the risk of ileus and intestinal obstruction from Ozempic.
A new complaint in the GLP-1 multidistrict litigation accuses Novo Nordisk of failing to warn patients about the risk of ileus and intestinal obstruction from Ozempic.
A Northern District of California judge dismissed a products liability lawsuit against Johnson & Johnson and Janssen Pharmaceuticals, ruling that plaintiffs failed to plead when their mother was exposed to Risperdal or discovered her cancer, leaving...
AbbVie’s trade secret suit against BeiGene survives a motion to dismiss, with the court finding the complaint plausibly alleged the company took reasonable measures to protect its cancer drug designs and described them with sufficient specificity.
A federal judge ruled the drugmaker's subpoenas to six hospital systems were irrelevant to its Contract Clause challenge to Missouri's law protecting contract pharmacy access to 340B discounts.
The District of Delaware granted summary judgment to Ameritas Life Insurance Corp., holding that a $10 million life insurance policy on Irene Sloat was void from inception because it lacked an insurable interest under Delaware law. The court also denied...
The Third Circuit on Friday upheld a district court's refusal to enjoin Samsung Bioepis from supplying a Cigna subsidiary with a private-label version of the ustekinumab biosimilar Pyzchiva, holding that Johnson & Johnson and Janssen Biotech had not...